Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
42.6M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
35.8M
-
Shares change
-
+2.61M
-
Total reported value, excl. options
-
$379M
-
Value change
-
+$27.7M
-
Put/Call ratio
-
0.28
-
Number of buys
-
31
-
Number of sells
-
-32
-
Price
-
$10.58
Significant Holders of Repare Therapeutics Inc. - Common Shares, no par value (RPTX) as of Q2 2023
87 filings reported holding RPTX - Repare Therapeutics Inc. - Common Shares, no par value as of Q2 2023.
Repare Therapeutics Inc. - Common Shares, no par value (RPTX) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.8M shares
of 42.6M outstanding shares and own 84.17% of the company stock.
Largest 10 shareholders include BVF INC/IL (8.29M shares), ORBIMED ADVISORS LLC (3.32M shares), CHI Advisors LLC (3M shares), Deep Track Capital, LP (2.73M shares), Versant Venture Management, LLC (2.65M shares), ARK Investment Management LLC (2.63M shares), Redmile Group, LLC (2.43M shares), MPM ASSET MANAGEMENT LLC (2.24M shares), T. Rowe Price Investment Management, Inc. (1.9M shares), and BIOIMPACT CAPITAL LLC (1.64M shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.